Just for laughs, tell us all the anti-viral drugs with well defined MOAs for specific well-studied viruses, such Covid-19, where drug levels far exceeded the level needed to inhibit viral replication but that failed miserably. Please exclude viruses that integrate into the host's DNA. That should be a very long list as you said it would take only take a dime for each example to make you a rich man. I mean, at $0.10 a pop you would need 10 million examples to get to a mere $1 million.
You don't seem to grasp that Covid is a virus that has been extensively studied and the protease that EDP-235 target whose activity is indispensable for viral replication. Inhibiting that protease has been proven to provide excellent efficacy. The EDP-235 concentration needed to inhibit Covid has been assessed and the bioavailability in animals as well as in humans from the phase I trial makes it crystal clear that EDP-235 greatly exceeds that concentration. The only concern I have is potential safety issues. However, such concerns are lessened greatly by the good phase I safety data and the fact treatment is a once-daily dosage over only for 5 days and doesn't requite a drug pump inhibitor like Paxlovid does. I urge you to short away.
The above quote is from unreviewed preprint that has just been submitted but it does provide good information.